Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.

被引：2
|
作者：
Vilbert, Maysa
Priantti, Jonathan N.
Madeira, Thiago
Moraes, Francisco Cezar A.
Tojjari, Alireza
Sahin, Ibrahim Halil
Cavalcante, Ludimila
Saeed, Anwaar
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Fed Univ Amazonas UFAM, Manaus, AM, Brazil
[3] Fed Univ Minas Gerais UFMG, Belo Horizonte, MG, Brazil
[4] Fed Univ Para UFPA, Belem, PA, Brazil
[5] Novant Hlth Canc Inst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-566-9718-9794; 261-492-3532-2370-7650-2700; 283-424-6846-271-2644; 283-2494; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 7; 4; 3; 2; 1614; 1597; 8; 1; 38092-27449; 38092-20072; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [31] Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis
    Landre, T.
    Des Guetz, G.
    Vergnenegre, A.
    Chouaid, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
    van Laarhoven, Hanneke W. M.
    Derks, Sarah
    CELL REPORTS MEDICINE, 2023, 4 (04)
  • [33] Radiomics for Predicting Response to First-Line Anti-PD1 Therapy in Advanced NSCLC
    Ackermann, C.
    Fornacon-Wood, I.
    Tay, R.
    Manoharan, P.
    Price, G.
    Lindsay, C.
    Faivre-Finn, C.
    Blackhall, F.
    Cobben, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S457 - S458
  • [34] PD-1/PD-L1 blockade as first line systematic therapy in locally advanced cutaneous head and neck squamous cell carcinoma
    Ho, E.
    Hu, K. S.
    Liu, C. Z.
    DeLacure, M.
    Persky, M.
    Jacobson, A.
    Ratner, D.
    Li, Z.
    Givi, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1183 - 1183
  • [35] Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy
    Chen, Wei
    Li, Dapeng
    Bian, Xuyu
    Wu, Yan
    Xu, Mengdan
    Wu, Mengyao
    Tao, Min
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 75 (01): : 207 - 218
  • [36] First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials
    Zhai, Jinzhao
    Lu, Jiangyue
    Zhang, Zhibo
    Wang, Yuan
    Li, Xiaoyan
    Zhang, Sujie
    Mu, Shuai
    Zhi, Xiaoyu
    Ge, Xiangwei
    Lu, Di
    Hu, Yi
    Wang, Jinliang
    CANCER MEDICINE, 2022, 11 (10): : 2043 - 2055
  • [37] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [38] PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1 negative metastatic lung adenocarcinoma: A real-world data
    Ge, Yihui
    Sun, Yuping
    Gao, Aiqin
    Li, Juan
    Wang, Dahai
    Wu, Jiake
    Sun, Yanxin
    Sun, Haifeng
    Sun, Haodong
    Li, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer
    Fan, Y.
    Xu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2149 - S2150
  • [40] Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma
    Rong Qiu
    Wenxi Wang
    Juan Li
    Yuxiang Wang
    Molecular Biology Reports, 2022, 49 : 6633 - 6645
12345